Antares Therapeutics has entered into a strategic collaboration with Novartis to discover, develop, and commercialize a new generation of small-molecule cancer therapies targeting proteins that have long been considered “undruggable.” The agreement marks a major milestone for the biotechnology company and highlights growing industry interest in tackling some of oncology’s most difficult drug targets.
Under the terms of the collaboration, Antares will receive an upfront payment of $105 million and could earn up to $1.8 billion in additional payments tied to option exercises, development, regulatory approvals, and commercial milestones. The company is also eligible to receive tiered royalties on future global net sales if products developed under the partnership reach the market.
The collaboration combines Antares’ expertise in precision drug discovery with Novartis’ global research, development, and commercialization capabilities. Together, the companies aim to accelerate the development of innovative cancer therapies for patients with limited treatment options.
As part of the agreement, Antares will lead the early-stage research using its proprietary drug discovery platform to identify and develop therapies against a limited number of oncology targets selected for the partnership. These targets have historically proven difficult for conventional drug discovery approaches, making them attractive but challenging opportunities for new cancer treatments. Novartis will have the option to advance successful drug candidates into later stages of development and commercialization.
The deal allows Antares to continue expanding its own pipeline while collaborating with one of the world’s largest pharmaceutical companies. Alongside the Novartis partnership, the company said it will continue advancing both its wholly owned and partnered portfolio of precision medicines for cancer and other serious diseases.
Antares Chief Executive Officer Dr. Adam Friedman said the company’s long-term goal has been to build a discovery platform capable of consistently producing first-in-class medicines against some of the most challenging biological targets. He said partnering with Novartis will allow Antares to expand the reach of its technology while benefiting from Novartis’ extensive experience in global drug development.
According to Friedman, the collaboration creates an opportunity to move promising therapies into the clinic more quickly than either company could achieve independently. He also credited Antares’ scientific team for developing highly selective drug candidates against targets that many researchers previously believed could not be effectively treated with small molecules.
The partnership is built around Antares’ proprietary drug discovery engine, which combines several advanced technologies, including covalent drug design, specialized screening libraries, chemical proteomics, structure-based computational chemistry, and machine learning tools. These capabilities are designed to identify highly selective compounds against complex biological targets that have traditionally resisted drug development.
Novartis sees the collaboration as an opportunity to strengthen its oncology research pipeline. Fiona Marshall, President of Biomedical Research at Novartis, said many of the most promising targets in cancer research have historically been considered undruggable, limiting treatment options for patients. She noted that combining Novartis’ research and development expertise with Antares’ innovative discovery platform could help unlock a new generation of targeted cancer therapies.
The agreement reflects a broader trend across the pharmaceutical industry, where large drugmakers are increasingly partnering with biotechnology companies that have specialized technologies capable of addressing difficult scientific challenges. Rather than relying solely on internal research, pharmaceutical companies are investing in external innovation to expand their pipelines and accelerate the development of first-in-class medicines.
For Antares, the partnership provides significant financial support while validating its discovery platform on a global stage. If successful, the collaboration could produce novel targeted therapies capable of treating cancers that currently have few effective treatment options, while further establishing the company as a leader in precision oncology drug discovery.